EVO
What one share of Evotec SE holds
Pharmaceutical Preparations
At Evotec, we envision drug discovery, preclinical development, and manufacturing as a seamless continuum. Our ambition is to lead the way by combining comprehensive disease understanding at the molecular level with cutting-edge technologies, transforming this knowledge into precise, life-changing medicines through collaborative partnerships.
Evotec SE’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $2.51 |
|---|---|
| Profit | −$0.33 |
| Capex (buildings and equipment) | $0.23 |
| Free cash flow | −$0.26 |
| Cash and investments | $1.38 |
| Debt | $0.91 |
| Book value | $2.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $1.67 | $0.14 | $0.12 | $0.04 | — | $1.79 |
| 2020 | $1.86 | $0.02 | $0.37 | −$0.20 | — | $2.70 |
| 2021 | $2.20 | $0.77 | $0.42 | $0.03 | — | $4.41 |
| 2022 | $2.24 | −$0.52 | $0.54 | $0.07 | — | $3.59 |
| 2023 | $2.39 | −$0.26 | $0.65 | −$0.54 | — | $3.50 |
| 2024 | $2.43 | −$0.60 | $0.36 | −$0.30 | — | $2.78 |
| 2025 | $2.51 | −$0.33 | $0.23 | −$0.26 | — | $2.69 |